MedX Secures $2.7M Lifeline to Fund Growth, Restructure Debt, and Target New Markets

MISSISSAUGA, Ontario – February 27, 2026 – MedX Health Corp. (TSX-V: MDX), a medical technology firm specializing in teledermatology, has successfully secured a significant capital injection, announcing the initial closing of a $2,700,000 non-brokered private placement. This move, part of a larger effort to raise up to $5,000,000, provides the company with vital funds to advance its strategic initiatives while navigating a challenging financial landscape.

The financing comes at a critical juncture for the company, which, despite having its proprietary skin-screening technology cleared by major global regulators, remains unprofitable. The proceeds are earmarked for a multi-pronged strategy: redeeming older debt, accelerating the development of its core technology, and launching an ambitious expansion into the booming occupational health sector.

A Financial Lifeline with Strings Attached

The financing structure involves the issuance of Series IV Convertible Loan Notes, which carry a 6% annual interest rate and mature on December 31, 2028. For investors, the key feature is the convertibility. Note holders can, at their option, convert the debt into units of the company at a price of $0.10 per unit.

This conversion price represents a significant premium over the company's recent stock performance, which saw its shares (MDX) trading near a 52-week low of $0.03 around the time of the announcement. While this premium might seem favorable, the underlying mechanics highlight the financial tightrope MedX is walking. The company’s latest financial reports show a pattern of increasing net losses, reaching $1.28 million in the third quarter of 2025 alone, with a trailing interest coverage ratio of -1.71, indicating that earnings are insufficient to cover interest payments.

Should the company's fortunes improve and its stock price rise above the conversion price, the conversion of these notes and the exercise of associated warrants will lead to the issuance of new shares, diluting the ownership stake of existing common shareholders. For a pre-profit tech company, such dilutive financing is often a necessary trade-off for survival and growth, providing the runway needed to execute its business plan and reach profitability.

Strategic Debt Management

A primary use of the new capital is to address MedX's existing debt obligations, specifically its Series I Convertible Loan Notes. The company issued $3.7 million of these notes in 2021, with an extended maturity date of December 31, 2025, for the outstanding $2.95 million. The Series IV placement provides a mechanism to manage this looming deadline.

Holders of the older Series I Notes are being given the option to surrender them in exchange for the new Series IV Notes. Any Series I Notes not surrendered will be redeemed using the proceeds from the new placement. This maneuver effectively allows MedX to refinance its debt, pushing the maturity date out to 2028 and simplifying its capital structure. It's a strategic move to clean up the balance sheet and provide greater financial flexibility over the next few years.

Targeting a New Frontier: Occupational Health

Beyond shoring up its finances, MedX is setting its sights on a significant new market: occupational health. The company has explicitly stated that funds will be used to build out its launch into this sector, a market poised for explosive growth. Industry reports project the global workplace safety and health market to surge from approximately $20 billion in 2025 to nearly $40 billion by 2030, expanding at a compound annual growth rate of over 12%.

This expansion is driven by stricter regulations, a greater corporate focus on employee wellness, and the adoption of technology to mitigate workplace risks. MedX's SIAscopy® on DermSecure® platform is uniquely positioned to serve this market. The non-invasive skin-screening technology could become a vital tool for companies with employees exposed to occupational hazards, such as outdoor workers in construction, agriculture, and transportation who have high levels of sun exposure and a corresponding risk of skin cancer.

By offering a quick, painless, and accurate screening tool that can be deployed in a corporate wellness setting, MedX aims to carve out a niche in this lucrative B2B market, moving beyond its traditional clinical focus and creating a new, potentially substantial revenue stream.

Bolstering Core Technology for a Digital Future

The funding will also reinforce the company's core technological advantage. MedX's SIAscopy® is the only technology that can non-invasively measure the concentration and distribution of key biomarkers like melanin, hemoglobin, and collagen in the skin. This proprietary edge, combined with its secure DermSecure® telemedicine platform, has earned it regulatory clearance in the United States (FDA), Canada, the European Union, Australia, and other key markets.

Continued investment is crucial to maintaining this lead in the rapidly evolving teledermatology space. Analysts, while forecasting continued unprofitability for the next few years, project that MedX's annual revenue could grow at an aggressive 53.3% per year. Achieving this growth depends on the company's ability to continually innovate and expand the capabilities of its platform.

The successful initial closing of $2.7 million is a vote of confidence from investors in this long-term vision. The final closing of the placement, which is subject to further subscriptions and regulatory approvals from bodies like the TSX Venture Exchange, will be a key indicator of the market's appetite for MedX's high-risk, high-reward strategy of balancing present financial pressures against future growth opportunities.